Nasdaq-listed VivoPower International PLC has confirmed the successful completion of a $19 million equity raise through the sale of common stock priced at $6.05 per share. The offering, executed at a premium to its last closing price, reflects growing institutional interest in the company’s pivot toward digital asset treasury management centered on XRP. The fresh […]Nasdaq-listed VivoPower International PLC has confirmed the successful completion of a $19 million equity raise through the sale of common stock priced at $6.05 per share. The offering, executed at a premium to its last closing price, reflects growing institutional interest in the company’s pivot toward digital asset treasury management centered on XRP. The fresh […]

VivoPower Strengthens XRP Future with $19 Million Strategic Raise

2025/10/03 08:30
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
XRP
  • VivoPower secures $19 million through an equity raise at $6.05 per share.
  • Funds will expand its XRP digital treasury strategy and reduce debt.
  • Long-term global investors signal confidence in the company’s XRP focus.

Nasdaq-listed VivoPower International PLC has confirmed the successful completion of a $19 million equity raise through the sale of common stock priced at $6.05 per share. The offering, executed at a premium to its last closing price, reflects growing institutional interest in the company’s pivot toward digital asset treasury management centered on XRP.

The fresh capital will play a dual role. Firstly, it will allow VivoPower to strengthen its XRP holdings as part of a structured digital treasury plan. Secondly, a portion of the proceeds will go toward retiring debt, creating a healthier balance sheet as the company pursues long-term growth.

Strong Support from Global Institutional Investors

Shares from the latest offering were placed with long-term institutional investors in both the United States and international markets. According to market watchers, this backing underscores strong confidence in VivoPower’s shift toward digital assets.

The fundraising comes in addition to a previously announced Regulation S offering led by His Royal Highness Prince Abdulaziz bin Turki bin Talal Al Saud, signaling that the company has secured significant interest from both private and institutional players.

The offering was carried out under a registration statement on Form F-1, which was declared effective by the U.S. Securities and Exchange Commission on May 27, 2025. A final prospectus was also filed with the SEC, ensuring compliance and transparency for participating investors.

VivoPower Adopts XRP For Treasury Plans

Founded in 2014 and publicly listed since 2016, VivoPower has built a global presence across the UK, Australia, North America, Europe, the Middle East, and Southeast Asia. The company is recognized as a sustainability-driven enterprise, with its B Corporation status reflecting its commitment to clean energy solutions.

Its two main business units, Tembo and Caret Digital, highlight this dual approach. Tembo delivers electric vehicle solutions for rugged fleet applications, while Caret Digital focuses on renewable power and digital asset mining.

The company now sees XRP as central to its treasury strategy, with plans to manage and hold the asset long-term. By aligning sustainability goals with blockchain adoption, VivoPower aims to play a role in expanding the XRP Ledger’s use in decentralized finance and real-world applications.

Also Read: XRP Price Targets $3.5 Following Massive 250 Million Whale Buying Activity

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3666
$1.3666$1.3666
+0.74%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09